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The existence of immunity to cancer was postu­
lated by the eminent scientists who helped to estab­
lish the discipline of immunology. In 1907 Clowes 
suggested that human resistance to cancer resulted 
from what we. today call "immune surveillance." 1•2 
During the ensuing 70 years the results obtained from 
experimental animal cancers and human cancers have 
greatly influenced the palatability of tumor-immunity 
theories.3·' Early optimism that immunity to cancer 
could be specifically induced waned and almost dis­
appeared when it was demonstrated that the rejection 
of cancer transplants resulted from transplantation 
immunity and not tumor immunity. A sustained 
wave of enthusiasm for immunity to cancer appeared 
after demonstrations that inbred animals could be 
immunized to cancers arising in the inbred strain.5· 6 
The objective of this paper is to try to reexamine 
many aspects of cancer immunology and to shift the 
emphasis currently placed on some of these aspects 
into other areas with greater potential for clinical 
application. This is not meant to be one of the numer­
ous reviews of cancer immunology but rather a bal­
anced presentation of alternative viewpoints which 
will ultimately tilt toward my viewpoint. 
The plan for the paper is as follows: ( I ) the types 
of contributions immunology has made to mankind 
will be briefly reviewed: (2) a general theory describ­
ing cancer immunity with some supporting evidence 
will be presented not once but twice: (3) finally the 
current status of immunotherapy of human cancer 
will be briefly mentioned. 
Co111ribwions o/Im111uno/ogy. 
A review of the major contributions of immu­
nology to humanity should offer a preview of what 
can reasonably be expected from future contributions 
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of this field to the understanding and control of can­
cer. The trademark of immunology is prevention of 
disease by immunization. With the discovery of anti­
biotics and their use in tissue cultures. a fresh attack 
upon many viral infections became possible. In the 
past two decades. the cultivation of viruses in vitro 
has resulted in the elimination of epidemics of po­
liomyelitis: infection with measles virus is less com­
mon. Where the human is the sole host and reservoir 
of an infection. immunization may lead to the eradi­
cation of a disease. This appears to be the attainable 
goal in smallpox where we are at the threshold of its 
eradication by intensive immunization and epidemio­
logic field work. 
While the trademark is immunization. the work 
horse of immunology is serology. lls use in diagnosis 
and blood banking alone are of critical importance to 
the functioning of our hospit<c1ls. A strike of all tech­
nicians doing serologic tests would paralyze our 
health care system. In addition to its diagnostic con­
tributions. immunology provides an important un­
derstanding of the pathogenesis of disease. 
A relatively new but potentially major contribu­
tion is in predicting susceptibility to disease. The 
association of certain transplantation antigens with 
specific disease states may be the forerunner of sero­
logic identification of disease-risk factors. 
When one turns to the role of immunology in 
therapy. the work seems harder and the results hardly 
optimal. This view is not meant to belittle the value of 
replacement therapy in certain immune deficiency 
diseases, or of immunosuppressive therapy in pre­
venting transplant rejection: rather it is intended to 
point out that cancer immunology is much, much 
more than immunotherapy. 
Grneral Frn1ures of" /111111uni1y 10 Cancer. 
All cancer immunology is inextricably linked to 
the existence of an antigenic difference between the 
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cancer cell and its closest normal "relative'' cells. 
Without such a difference, immunology has no entry 
into the cancer field. 
The transformation of a normal cell to a cancer 
cell is probably accompanied by an antigenic change. 
This transformation may occur frequently in all of us. 
With a properly functioning immune system, the an­
tigenic change or changes in the cancer cells are rec­
ognized and following recognition an effective anti­
cancer cell immune response destroys the malignant 
cells. Appearance of clinical cancer is thus considered 
to be a prima facie case of a failure of normally 
operating immunologic mechanisms. 
Ei;idence Supporting Immune Surveillance. 
Origins for cancer antigens are not hard to find. 
Oncogenic viruses are obvious sources of extraneous 
antigenic material incorporated into cancer cells. 
While no human oncogenic virus has been clearly 
identified, several viruses are viewed with suspicion. 
Chemical compounds play an important role in the 
initiation of human cancer, and for many years these 
carcinogens included many compounds that are also 
mutagens. Recently a bacterial test for detecting 
chemical mutagens has shown that almost every 
known chemical carcinogen is either a mutagenic 
agent or is metabolized to a mutagen.' Chemical 
carcinogen-induced changes in the bases of deoxyri­
bonucleic acid (DNA) can result in the synthesis of 
abnormal. that is, antigenic, proteins. Similarly. 
physical agents such as ultraviolet and x-irradiation 
are also known carcinogens and mutagens. 
Amongst the wide variety of human cancers, an 
impressive list of cancer-associated "time and place" 
antigens have been detected.•-10 The carcinoembry­
onic antigen of the gastrointestinal tract. alpha-feto­
protein. chorionic gonadotropin, antidiuretic hor­
mone. and parathormone are examples of normal 
product made by cancers that are either abnormal 
for postnatal life or for that type of cell. 
As we move to consider the evidence for the 
existence of immune cancer-rejection systems, we 
need to rely on negative observations. It is impossible 
to demonstrate that we are cancer-free as a result of 
active recognition and destruction of small clones of 
cancer cells. but strong circumstantial evidence 
points to such immune mechanisms. Patients who are 
recipients of organ transplants have a high risk of 
subsequently developing a malignant disease11 ·12 : 
these patients are estimated to be at least 25 times 
more likely to develop cancer than the normal popu­
lation. 
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An additional group of patients at high risk for 
developing cancer are those individuals with im­
munodeficiency diseases. From 5% to I 0% of patients 
with sex-linked agammaglobulinemia, combined im­
munodeficiency disease, Wiskott-Aldrich, or ataxia 
telangiectasia will develop clinical malignant disease. 
Further but less definite indications that we are pro­
tected by immune mechanisms include the observa­
tions that chemical carcinogens may be immunosup­
pressive,1• the claims of cutaneous anergy in patients 
with neoplastic disease, 1'- 1' and the frequently stated 
view that patients with cancer have an increased sus­
ceptibility to infection. 1• 
The last element to be considered in the con­
struction of an immunologic lattice for the contain­
ment of cancer is the alteration of the course of 
cancer by immunologic methods-immunotherapy. 
Attempts to stimulate a specific immune response1' 
and to stimulate the entire immune response by 
agents like bacille Calmette Guerin (BCG )'0 have 
been extensively performed. In 1971, a comprehen­
sive review was published by Yashpie,'1 and the re­
port of a conference entitled. "lmmunotherapy of 
Cancer: Present Status of Trials in Man," held in 
Washington in October, 1976, is to be published. 
How effective is immunotherapy for human can­
cer? It is important to realize that the concept of the 
"proof of the pudding is in the eating" is as much 
determined by how hungry one is as by the quality of 
the pudding. Rather than enthuse about immuno­
therapy, I prefer to accept its present meagre results 
as a challenge to reexamine our entire position. I will 
also consider immunology with respect to prevention, 
pathogenesis, early diagnosis, treatment monitoring 
aids, and immunotherapy. 
Prevention of Human Cancer by Vaccines. 
An extensive review of the possibilities in this 
area was recently published." At least two major 
obstacles need to be overcome before vaccines for 
human cancer become a reality. First and foremost 
the link between a human virus and the cancer it 
causes needs to be firmly established. Then the virus 
can be developed into a vaccine-living, killed. or 
subunit. The second problem is to determine who 
should receive the vaccine. Since the incidence of any 
one kind of carcinoma is relatively low, methods are 
needed to identify the high-risk groups. Where the 
prevalence of a carcinoma may be 5 to 10 persons per 
100,000, it would be unacceptable to try to immunize 
the whole population. 
Where a viral-associated neoplasm behaves like 
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a communicable infectious disease, a vaccine could 
be very helpful. Such a situation exists in the poultry 
industry. A DNA herpes-like virus (Marek's disease 
virus) is manufactured into a fully infectious form in 
the feather follicle of the chicken. In addition this 
virus spreads within the chicken and causes a fatal 
lymphoreticular disease; it also spreads amongst 
chickens and can wipe out a flock. An effective vac­
cine has been prepared from an apparently harmless 
herpes virus of turkeys. This vaccine protects the 
chickens against Marek's disease!• 
The Pathogenesis of Cancer. 
Immunologists searching for human cancer anti­
gens have made an astounding, although largely ig­
nored, contribution to our understanding of the 
pathogenesis of cancer. Despite years of search by 
numerous competent investigators, a cancer-specific 
antigen has not been isolated for any human cancer. 
Although the search for cancer-specific antigens is 
too important to be abandoned, the possibility that 
specific cancer antigens do not exist must be faced. 
Instead of cancer-specific antigens, cancer-associated 
antigens have been found. Some of these antigens are 
considered time antigens. A cancer cell makes fetal 
alkaline phosphatase, or a fetal pyruvate kinase 
isozyme, or embryonic antigens, or structures such as 
alpha-fetoproteins; place antigens also are made. 
Thus a variety of normal hormones are made by 
malignant cells derived from cells that have ceased 
making these products. Frequently these hormones 
produce symptoms in the patient, a paraneoplastic 
syndrome. Were we to have the full catalog of normal 
gene products made from conception to maturity, it 
is possible that a time or place antigen or both could 
be associated with every human cancer. The finding 
of time and place cancer-associated antigens instead 
of cancer-specific antigens fits in with an intriguing 
new concept of the pathogenesis of cancer;• which as 
its essential feature regards cancer as a programming 
error. Carcinogenesis is not a mutation to new struc­
tures but rather a reactivation of genetic programs 
that were terminated a long time ago. In this view 
viruses, chemicals, and physical agents act by going 
· into the "old book" section of the cell's DNA library 
and activating something long dormant. 
It is possible to estimate the percent of the infor­
mational DNA that is being actively transcribed by 
cells. There is no difference in the amount of DNA 
active in the blastula phase, the gastrula phase, or the 
adult cells. About 3% of the DNA is being used, but 
the 3% used in the gastrula phase cells is not identical 
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to the 3% used by the blastula cells. Thus normal 
development consists of the orderly and sequential 
production and elimination of portions of the DNA 
program. 
Can programs be initiated? Dr. Ruddy referred 
to androgen treatment of hereditary angioedema. 
The administration of an androgen leads to synthesis 
of a significant amount of a protein necessary to 
inhibit spontaneous activation of the complement 
system; other examples exist, perhaps the best being 
the reactivation of the information locked up within a 
cell nucleus as reported by Gurdon.2' Trans­
plantation of organelles produced striking results 
when the nucleus of a fertilized frog ovum was re­
moved and replaced by the nucleus of a mature frog 
muscle cell. The microsurgically treated cell was then 
restored to its proper environment, and development 
of the ovum resulted in the formation of a tadpole. 
All the information for this development was uncov­
ered in an orderly fashion from the mature nucleus of 
a differentiated cell. Similar results have been ob­
tained when the nucleus from a mature frog lym­
phocyte was transplanted into an enucleated ferti­
lized frog ovum. 
Our society seems to have more difficulty in for­
mulating the correct questions than it does in provid­
ing the answers to these questions. The finding of 
several cancer-associated antigens emphasizes that 
cancer immunologists must continue to examine 
serologically the early stages of development with the 
objective of identifying additional tumor-associated 
antigens that in turn may be critical in establishing 
valid early diagnostic tests for cancer. 
The Nature of the Immune Defect in Cancer. 
The failure to demonstrate an effective immuno­
therapeutic method requires that the defects in the 
immune surveillance and rejection system be exam­
ined again with respect to cancer. 
Does the patient who develops a carcinoma of 
the lung, or breast, or stomach or other organs have a 
defect that is applicable to the recognition and reac­
tion to many antigens or is the defect confined to the 
antigen or antigens associated with that particular 
cancer? This is not a trivial question since the direc­
tion for future immunotherapy depends on the an­
swer. Arguments in favor of a broad defect are the 
high incidence of neoplasm in transplant patients and 
in those with immune deficiency diseases, but the 
interpretation of this evidence is not decisive. Cy­
totoxic immunotherapy is not exclusively immuno­
suppressive. It may interfere with DNA repair mech-
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an isms which if unchecked could cause malignancy as 
seen in xeroderma pigmentosa. 26 These patients have 
a very high incidence of neoplasms of the skin, and 
severe impairment of the ability to repair the damage 
in DNA caused by ultraviolet irradiation. Many of 
the drugs used in immunosuppression may also inter­
fere with DNA repair mechanisms. 
The evidence suggesting that there is no broad 
immune defect in cancer patients is drawn from the 
incidence of infection in patients with solid neo­
plasms. Since the earliest days of immunology, in­
fection has pointed to the areas where immune de­
fects exist, and it is unusual to see clinically 
significant immune defects without concomitant fre­
quent infection. Indeed the defects may be so subtle, 
as in sickle cell disease, that increased susceptibility 
to infection is recognized long before the nature of 
the immune defect is discovered. 
Contrary to general opinion, infection is not a 
common problem in the patient with solid cancers, 
although infection certainly occurs when large masses 
obstruct a passageway or become necrotic. If exten­
sive chemotherapy renders the patient gran­
ulocytopenic, or if large doses of steroids are given, 
infection occurs, but under other circumstances, in­
fection in a non-terminal cancer patient is rare. Ac­
counts of infection in cancer patients are pre­
dominantly those of patients with leukemia, 
lymphoma, and myelorna. Of 93 patients with asper­
gillosis, only 14 had solid tumors." Of these, 11 were 
receiving steroids and nine were receiving cytotoxic 
drugs. Another recent report'" shows that 31 of 35 
patients treated for infection with sulfamethoxazole­
trimethoprirn had hematologic malignancies; so it 
goes with all reports of infection in cancer patients. 
It appears to me unlikely that the overwhelming 
majority of patients with solid tumors have a large 
blind spot in their immune system. Skin testing for 
anergy, counting T and B lymphocytes, and stimu­
lating lymphocytes with mitogens can probably be 
safely discontinued or replaced by looking for the 
real defect in the immune system in cancer patients. 
This leads to the second question. How does an 
antigenic cancer escape detection') The answer to this 
question is beset with technical difficulties. The re­
ports of two workshops29· 30 designed to evaluate the 
results of in vitro cytotoxicity tests for cancer cells are 
gloomy. More emphasis needs to be placed upon 
technical improvements in the culturing of cancer 
cells and in determining their in vitro susceptibility to 
antibody and to lymphocytes and macrophages. 
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Our understanding of this area is intimately tied 
to our efforts in human cancer immunotherapy. An 
outline of how a cancer breaks through or may break 
through is of value even though it is purely specula­
tive. Early studies in malignant melanoma" stressed 
the importance of humoral antibodies. Patients with 
localized melanoma were reported to have antibody 
which reacted with melanoma cells while patients 
with disseminated melanoma generally lacked these 
antibodies. Using in vitro techniques, the Hellstroms 
demonstrated a more complex Trojan Horse type of 
immunologic arrangement" in which lymphocytes 
from a cancer patient could destroy in vitro cancer 
cells removed from that patient. This cellular immune 
reaction could be inhibited by antibody present in the 
serum of that cancer patient and from these observa­
tions a dual immune system was formulated-an­
tibody could protect the cancer, and cellular immun­
ity could destroy the cancer. Further modifications 
have been made in both the serum and cellular as­
pects, but the basic premise remains that the destruc­
tion or growth of a cancer depends upon the relative 
strengths of two types of immune reactions. This 
point should be returned to in considering the results 
of immunotherapy. 
Immunology and Early Diagnosis of Cancer. 
Early diagnosis implies identification of the pres­
ence and location of malignant cells at a time when 
curative treatment can be performed. Today none of 
the immunologic tests for cancer-associated antigens 
are sensitive and specific enough to meet this require­
ment. 
The nature of the immunologic tests for cancer­
associated antigens is qualitatively different from 
tests measuring levels of liver enzymes or bone en­
zymes. In the latter tests, it is unlikely that a small 
mass could raise the level of normally present en­
zymes to an abnormal level; that is, there is a high 
background of normal activity that obscures the sim­
ilar activity of the neoplastic cells. In the immuno­
logic tests, the search is for fetal antigens in which the 
background levels should be low. This is an area in 
which future progress may produce valuable results. 
f 111111unologic Treatment Monitoring A ids. 
Three radioimmunoassay tests are currently of 
great value in the management of patients with can-
cer. 
The carcinoembryonic antigen (CEA) test is of 
great assistance in management of some patients with 
colorectal carcinoma. Where the level is elevated pre­
operatively, the postoperative levels are useful in as-
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sessing the recurrence of disease and the response to 
therapy. We are not recommending adjuvant post­
operative chemotherapy, but an elevation in the CEA 
is one indication to search for the location of the 
recurrence and for initiation of therapy. 
Radioimmunoassay of chorionic gonadotropins 
has long been known to be essential in planning the 
treatment of choriocarcinoma. The radio­
immunoassays for alpha-fetoprotein and for the B­
subunit of chorionic gonadotropin add a major new 
dimension to our management of patients with testic­
ular cancer. Decisions about starting chemotherapy 
and the selection of the chemotherapy drugs used are 
greatly influenced by the results of these immunologic 
tests. 
lmmunotherapy of Cancer. 
I have not allotted much space to the analysis of 
cancer immunotherapy. Many techniques-some 
simple, some complex, and some very ingenious-are 
being used to either treat human cancer or to prevent 
its recurrence. 
The experimental studies of BCG immunization 
in the guinea pig" illustrate the potential value and 
the limitations of immunotherapy. In this system, 
injection of living Mycobacterium bovis BCG into the 
tumor residing in an animal capable of developing 
cellular reactivity to BCG, and at a time when the 
tumor is small, results in a marked decrease in the 
number of tumor-transplantation takes. Many exper­
imental animal systems carefully designed to demon­
strate an effect of immunotherapy have been pub­
lished. The literature on human cancer 
immunotherapy trials is enormous; its abundance 
makes it difficult to discount. In my view the effec­
tiveness of any immunotherapeutic procedure in hu­
man cancer has yet to be demonstrated. There is great 
interest in studying the results reported at the confer­
ence "lmmunotherapy of Cancer: Present Status of 
Trials in Man." 
Predicting the future course of immunothera­
pists is hazardous. The mood or moving spirit seems 
to indicate a great disenchantment with BCG and its 
allied products. A shift to Corynebacterium parvu/um 
is underway, but it is probably too toxic to gain wide 
acceptance. The newest bacterial entry is the pseudo­
monas vaccine. The direction seems to be to go 
through Bergey's Manual, a task that could involve 
generations. 
Ironically BCG is being rejected as uncritically 
as it was accepted. If we are to be able to interpret an 
immunotherapy trial properly, we need to know 
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more than the change in size of a cancer mass or the 
duration of survival. We need measurements of the 
changes in the levels of antitumor blocking antibody, 
unblocking antibody, and cellular cytotoxicity and 
cellular suppression. With this information we can 
learn how to stimulate selectively the portion of the 
immune response that destroys cancer without stimu­
lating the immune response that aids cancer. 
Conclusions. 
Immunology provides a valuable tool as a treat­
ment monitoring aid in many cancers. 
The likelihood of an effective cancer vaccine is 
remote and requires identification of both an onco­
genic virus and a susceptible subgroup. 
The failure to find cancer antigens and the abun­
dance of cancer-associated antigens suggest that can­
cer may be a programming error and potentially re­
versible. 
Immunology is likely to provide better and effec­
tive early diagnostic tests. 
The major need in immunotherapy is laboratory 
support to measure the effects of therapy upon anti­
tumor immune response. 
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